The Investment Dilemma: The “Must-Play” Game of the Era. AI has emerged as the defining strategic priority and a primary target for capital allocation across industries. From pharmaceuticals to retail, companies are aggressively deploying Generative AI and automation at a
Continue Reading
Antibody-Drug Conjugates (ADCs) are among the most promising precision therapies today. By combining the high targeting capability of monoclonal antibodies with the potent cytotoxicity of small-molecule drugs, they have become a new focal point in the R&D of cancer and
Continue Reading
ADC Opportunities and Challenges: High Technical Barriers are the Cornerstone of Long-Term CDMO Advantage. For pharmaceutical CDMOs, ADCs present immense commercial opportunities. On one hand, the rapid expansion of global clinical pipelines is driving outsourcing demand. On the other hand,
Continue Reading
The New Game for CDMOs: Shifting from Capacity Scale to Knowledge Capabilities The pharmaceutical CDMO industry is currently navigating an unprecedented wave of transformation. Over the past two years, multiple industry reports have consistently indicated that the competitive threshold has
Continue Reading
Article Categories
Article Categories
Article Categories
Latest Articles
Follow Us
